SRR1437306
GTEX
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- GTEX
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- GTEX
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- OXIDATIVE_PHOSPHORYLATION+0.538
- PANCREAS_BETA_CELLS+0.402
- FATTY_ACID_METABOLISM+0.367
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.363
- KRAS_SIGNALING_DN+0.338
- SPERMATOGENESIS+0.280
- ADIPOGENESIS+0.252
- BILE_ACID_METABOLISM+0.219
- MYOGENESIS+0.202
- ESTROGEN_RESPONSE_LATE+0.150
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.576
- IL6_JAK_STAT3_SIGNALING-0.516
- INTERFERON_GAMMA_RESPONSE-0.508
- WNT_BETA_CATENIN_SIGNALING-0.479
- TNFA_SIGNALING_VIA_NFKB-0.412
- MITOTIC_SPINDLE-0.404
- G2M_CHECKPOINT-0.392
- INFLAMMATORY_RESPONSE-0.372
- ALLOGRAFT_REJECTION-0.358
- NOTCH_SIGNALING-0.350
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR1415095 | GTEX | — | 0.994 |
| 2 | SRR1318426 | GTEX | — | 0.957 |
| 3 | SRR1354689 | GTEX | — | 0.927 |
| 4 | SRR1435020 | GTEX | — | 0.919 |
| 5 | SRR1402900 | GTEX | — | 0.916 |
| 6 | SRR1471817 | GTEX | — | 0.915 |
| 7 | SRR1368772 | GTEX | — | 0.914 |
| 8 | SRR1435293 | GTEX | — | 0.906 |
| 9 | SRR1420984 | GTEX | — | 0.906 |
| 10 | SRR807591 | GTEX | — | 0.903 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 15 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| OXIDATIVE_PHOSPHORYLATION | 0.538 | Remibrutinib | — uncovered |
| PANCREAS_BETA_CELLS | 0.402 | Cobimetinib | — uncovered |
| FATTY_ACID_METABOLISM | 0.367 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.363 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.338 | Remibrutinib | — uncovered |
| SPERMATOGENESIS | 0.280 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.252 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.219 | Inavolisib | — uncovered |
| MYOGENESIS | 0.202 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.150 | Idelalisib | — uncovered |
| PEROXISOME | 0.143 | Idelalisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.087 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.058 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.018 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.017 | Inavolisib | — uncovered |